The results of the pivotal Phase 3 AURORA 1 trial, evaluating voclosporin for lupus nephritis, were published on January 1, 2022. This double-blind, randomised, multicentre, placebo-controlled study assessed the efficacy and safety of voclosporin against placebo, marking a significant milestone for the drug in this challenging autoimmune disease.
Background
Voclosporin, also known by its brand name Lupkynis, is an immunosuppressant investigated for the treatment of lupus nephritis. Lupus nephritis is a severe and potentially life-threatening complication of systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. It specifically affects the kidneys, leading to inflammation and damage that can result in chronic kidney disease and end-stage renal disease if not effectively managed. Current treatments often involve corticosteroids and other immunosuppressants, but there remains a significant unmet need for more targeted and effective therapies with improved safety profiles.
Trial design
The AURORA 1 trial was a pivotal Phase 3, double-blind, randomised, multicentre, placebo-controlled study. Its primary objective was to evaluate the efficacy and safety of voclosporin compared to placebo in participants diagnosed with active lupus nephritis. The trial design aimed to rigorously assess whether voclosporin could achieve superior renal response rates and demonstrate an acceptable safety profile over a defined treatment period, providing robust evidence for its potential clinical utility.
What this means
The publication of the AURORA 1 trial results provides clinicians and researchers with detailed efficacy and safety data for voclosporin in the treatment of lupus nephritis. As a pivotal Phase 3 study, these findings are crucial for understanding the drug's potential role in managing this challenging autoimmune kidney disease. The positive assessment of both efficacy and safety versus placebo, as highlighted in the publication, suggests that voclosporin could offer a valuable new therapeutic option for patients suffering from lupus nephritis, potentially improving renal outcomes and quality of life. This data is also vital for informing regulatory bodies in their review processes for potential approval and widespread clinical use.
Source
The information for this article is based on the publication of the AURORA 1 trial results in The Lancet, as indexed on PubMed. The publication, titled "Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial," was made available on January 1, 2022, via pubmed.ncbi.nlm.nih.gov. This source serves as the primary reference for the reported trial outcomes and design details.